6ix — Find Your Next Investment

Discover investor relations events, company profiles, and opportunities on 6ix. Connect with public companies and attend live investor events.

Please enable JavaScript to use all features of 6ix.com.

Oorspronkelijke tekst

Deze vertaling beoordelen

Je feedback wordt gebruikt om Google Translate te verbeteren

Latest Press Releases

Time	Headline
Just now	New Study Showed Consistent Glycemic Outcomes Across Sensors Integrated with MiniMed 780G System
Just now	Edible Garden Starts Shipping New Fresh-Cut Herb Program with Target
Just now	Laser Photonics and Fonon Technologies Highlight Compact Laser Marking Solution for Defense Logistics Support
Just now	NewGenIVF Announces Strategic Investment Agreement with Tech Veteran Andy Cheung-Led K25.ai, an AI-Powered Live-Streaming Prediction Market, at US$100 Million Valuation
1m ago	Ruanyun Edai Technology Strategic Associate Link Door Smart Company Signs Saudi Procurement and Service Agreement for HanLink Chinese Learning Platform

About

30.22USD+1.96 +6.94%

Closed • Updated at 13:10 GMT+00:00

Market Cap$1.47B

Volume789.4K

Beta2.37

RSI65.66

Gross Margin89.85%

Health TechnologyBiotechnology

Urogen Pharma Ltd. — investor relations, events, news, and company updates on 6ix.

Latest News

UroGen Reports 94.5% Six-Month Duration of Response in Phase 3 UTOPIA Trial, Advancing UGN-103 Toward Potential Approval in Recurrent Low-Grade Intermediate-Risk NMIBC

UroGen Reports ZUSDURI™ Revenue More Than Doubled Quarter-over-Quarter and Provides First Quarter 2026 Financial Results and Highlights

UroGen Pharma to Report First Quarter 2026 Financial Results on Wednesday, May 6th, 2026

UroGen Launches LG-UTUC Luminaries Initiative Recognizing Excellence and Leadership in Treatment of Patients with Low-Grade Upper Tract Urothelial Cancer

Journal of Urology Publishes ENVISION Trial Results Showing 72.2% 24-Month Duration of Response with ZUSDURI

Community Chat

Ask AI